Pulmocide has raised $122M in total funding. Latest round: Series C. Backed by Jeito Capital, Adjuvant Capital, Asahi Kasei Pharma.
Pulmocide funding overview
Pulmocide has raised $122M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in May 2021. The round record for Pulmocide runs through 2021; nothing later has been disclosed. Investors on record include Jeito Capital, Adjuvant Capital, Asahi Kasei Pharma, SV Health Investors, Johnson & Johnson Innovation. 5 distinct backers are named across the disclosed rounds.
Pulmocide at a glance
Total raised
$122M
Latest round
Series C
Latest round date
May 2021
Notable investors
Jeito Capital, Adjuvant Capital, Asahi Kasei Pharma, SV Health Investors, Johnson & Johnson Innovation
Frequently asked about Pulmocide funding
How much has Pulmocide raised?
Pulmocide has raised $122M in total disclosed funding across the rounds on record.
Who has invested in Pulmocide?
Jeito Capital, Adjuvant Capital, Asahi Kasei Pharma, SV Health Investors, Johnson & Johnson Innovation are named among the investors backing Pulmocide.
What was the latest Pulmocide funding round?
The most recent disclosed round is a Series C, announced in May 2021.
Where is Pulmocide based?
No headquarters location is disclosed for Pulmocide.
When did Pulmocide last raise?
The last disclosed Pulmocide round closed in May 2021 at Series C.
Totals shown for Pulmocide aggregate every disclosed round on file. To see how that compares, browse the companies and the investors behind them below.
